Skip to main content
Fig. 5 | Orphanet Journal of Rare Diseases

Fig. 5

From: An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

Fig. 5

eGFR over time by patient. Dashed line, cardiac involvement; solid line, no cardiac involvement. Patients with values below the lower limit of quantification (< X) or above the upper limit of quantification (> X) have been plotted as values of X. Patient 102 reached end-stage renal disease and required double renal transplant after 3 years at which point their eGFR data were censored. AA, serum amyloid A; ApoAI, apolipoprotein A-I; AFib, fibrinogen-a alpha chain; AL, immunoglobulin light chain; ATTR, transthyretin; eGFR, estimated glomerular filtration rate

Back to article page